Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tropical Influenza Control Strategies for the Elderly (TROPICS1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02655874
Recruitment Status : Completed
First Posted : January 14, 2016
Last Update Posted : November 14, 2017
Sponsor:
Collaborator:
National Healthcare Group, Singapore
Information provided by (Responsible Party):
Tan Tock Seng Hospital

Brief Summary:

TROPICS1 is a randomized, observer-blind, active comparator-controlled, single-center, Phase IV trial in 200 participants aged ≥65 years. The control group will receive a standard dose licensed trivalent inactivated influenza vaccine at day 1, and an active-comparator (Tetanus-diphtheria-pertussis vaccine) at day 180. Participants in the experimental group will receive the same influenza vaccine at day 1 and day 180. Endpoints are immunological, and include measures of haemagglutination-inhibition (HI) titres, micro-neutralisation titres and cell-mediated immunity at 4 time points after the initial vaccination up to Day 360. The primary hypothesis is that participants receiving an influenza booster at day 180 will achieve superior influenza seroprotection (HI titre ≥1:40) at day 208, compared to controls.

The World Health Organization (WHO) estimates the global annual burden from seasonal influenza as 1 billion infections, with 3-5 million severe cases and 300,000-500,000 deaths. The pattern and impact of these infections varies considerably with climate. In temperate countries, influenza epidemics characteristically occur during the cold winter months, while in sub-tropical countries, they coincide with the rainy seasons. Closer to the equator, influenza virus activity is more complex. In Singapore, biannual epidemics are usual, but with continuous transmission year-round. Bi-annual epidemics, tri-annual epidemics and year round virus activity have also been described in other tropical countries, from Indonesia and Malaysia to Peru and Mexico.

There is no published data reporting year-round influenza vaccine effectiveness in the elderly from countries with continuous influenza virus activity. Despite numerous studies worldwide exploring the HI antibody response to influenza vaccination, the majority of these do not continue follow up beyond seroconversion (21-28 days). However, of the few available, HI antibody titres declined following influenza vaccination in the elderly, such that within 6-12 months geometric mean titres approached pre-vaccination levels. With biannual epidemics and year-round transmission in tropical regions, year-round seroprotection may be important to reduce influenza infections in this environment. A six-monthly vaccination cycle would correspond with the decline in vaccine-induced seroprotection in the elderly, and the 6-monthly periodicity of outbreaks in Singapore and other tropical countries.


Condition or disease Intervention/treatment Phase
Influenza, Human Biological: Influenza vaccine Biological: Tetanus-diphtheria-pertussis vaccine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Single-centre, Randomised, Observer-blind, Active Comparator-controlled, Superiority Trial of the Immune Response to Six-monthly Versus Annual Standard Dose Inactivated Trivalent Influenza Vaccination in the Elderly
Actual Study Start Date : May 2016
Actual Primary Completion Date : June 2017
Actual Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: Six-monthly influenza vaccine
Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and 180
Biological: Influenza vaccine
Administered at day 1

Biological: Influenza vaccine
Administered at day 180

Active Comparator: Annual influenza vaccine
Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and an active-comparator (Tetanus-diphtheria-pertussis) at day 180
Biological: Influenza vaccine
Administered at day 1

Biological: Tetanus-diphtheria-pertussis vaccine
Administered at day 180




Primary Outcome Measures :
  1. Seroprotection (Proportion of subjects with HI titre ≥1:40 (1/dil) at day 208 post-primary vaccination for each of the influenza strains present in the administered influenza vaccine) [ Time Frame: Day 208 post-vaccination ]
    Proportion of subjects with HI titre ≥1:40 (1/dil) at day 208 post-primary vaccination for each of the influenza strains present in the administered influenza vaccine.


Secondary Outcome Measures :
  1. Geometric mean titres [ Time Frame: Day 208 to 360 post-vaccination ]
    Comparison by vaccination group of Geometric mean titres (GMTs) post-primary vaccination against homologous and heterologous influenza strains to those present in the administered influenza vaccine.

  2. Geometric mean ratio [ Time Frame: Day 208 to 360 post-vaccination ]
    Comparison by vaccination group of the Geometric mean ratio (GMR) post-primary vaccination against homologous and heterologous influenza strains to those present in the administered influenza vaccine.

  3. Seroprotection (Proportion of subjects with HI titre ≥1:40 (1/dil) at day 208 post-primary vaccination for each of the influenza strains present in the administered influenza vaccine) [ Time Frame: Day 360 post-vaccination ]
    Comparison by vaccination group of the proportion of subjects with HI titre ≥1:40 (1/dil) at day 360 post-primary vaccination for each of the influenza strains present in the administered influenza vaccine.

  4. Seroconversion (Proportion of subjects achieving seroconversion after vaccination for each of the influenza strains present in the administered influenza vaccine) [ Time Frame: Day 208 to 360 post-vaccination ]
    Comparison by vaccination group of the proportion of subjects achieving seroconversion after vaccination for each of the influenza strains present in the administered influenza vaccine. Seroconversion is defined as a pre-vaccination HI titre < 1:10 and a post vaccination titre ≥1:40, or a pre-vaccination titre > 1:10 and a minimum fourfold rise in HI titre.

  5. Micro-neutralization titres [ Time Frame: Day 208 to 360 post-vaccination ]
    Comparison by vaccination group of Micro-neutralization titres post-primary vaccination against strains present in the administered influenza vaccine.

  6. Influenza-like illness [ Time Frame: Day 208 to 360 post-vaccination ]
    Comparison by vaccination group of the number of subjects reporting an influenza-like illness

  7. Influenza infection [ Time Frame: Day 208 to 360 post-vaccination ]
    Comparison by vaccination group of the number of subjects with PCR confirmed influenza infection

  8. Healthcare utilization [ Time Frame: Day 180 to 360 post-vaccination ]
    Comparison by vaccination group of the number of subjects reporting healthcare utilization. This is defined as unscheduled physician visits, emergency room visits and hospitlizations.

  9. Solicited and unsolicited adverse events [ Time Frame: Day 1 to 7 and day 180 to 187 ]
    Frequency and severity of solicited local (injection site) and systemic adverse events for 7 days post-vaccination

  10. Serious adverse events [ Time Frame: Day 1 to 28, and day 180 to 208 ]
    A serious adverse event is defined as any untoward medical occurrence that is an important event.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age ≥65 years on the day of inclusion
  2. No influenza vaccination in the previous 10 months
  3. No tetanus, diphtheria or pertussis vaccine in the previous 1 year
  4. No virologically confirmed influenza infection in the previous 10 months
  5. Able to provide written informed consent
  6. Able to attend all scheduled visits and comply with all trial procedures

Exclusion Criteria:

  1. Participation in the 4 weeks preceding the first trial vaccination or participation during the present trial period in another trial investigating a vaccine, drug, medical device, or medical procedure
  2. History of a life threatening reaction to the vaccine used in the trial, or to a vaccine containing any of the same substances
  3. Known systemic hypersensitivity to any of the vaccine components, including:

    • Egg protein (eggs or egg products)
    • Chicken products
    • Formaldehyde
    • Neomycin or kanamycin
    • Octoxinol 9 (Triton X-100)
    • Cetyltrimethylammonium bromide (CTAB)
  4. History of Guillain-Barré syndrome (GBS) within 6 weeks following previous influenza vaccination
  5. Acute respiratory infection on the day of enrolment
  6. Moderate or severe acute illness/infection (according to investigator judgement) on the day of vaccination, or febrile illness (temperature ≥ 37.5°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
  7. Self-reported thrombocytopenia, contraindicating Intramuscular vaccination
  8. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding six months; or long-term systemic corticosteroid therapy (prednisolone ≥ 7.5mg/day or equivalent for more than 2 consecutive weeks within the past 3 months)
  9. Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
  10. Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
  11. Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures in the opinion of the Investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02655874


Locations
Layout table for location information
Singapore
Institute of Infectious Disease and Epidemiology, Tan Tock Seng Hospital
Singapore, Singapore
Sponsors and Collaborators
Tan Tock Seng Hospital
National Healthcare Group, Singapore
Investigators
Layout table for investigator information
Principal Investigator: Barnaby Young Tan Tock Seng Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Tan Tock Seng Hospital
ClinicalTrials.gov Identifier: NCT02655874     History of Changes
Other Study ID Numbers: 2015/01047
First Posted: January 14, 2016    Key Record Dates
Last Update Posted: November 14, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Tan Tock Seng Hospital:
Seasonal Influenza
Antibody response
Influenza Vaccines
Hemagglutination Inhibition
Elderly
immunosenescence
Tropics
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs